Last edition
News about " EGFR PACC mutations"
ArriVent's FURVENT Phase 3 Trial Misses Primary PFS Endpoint
ArriVent’s FURVENT Phase 3 trial of firmonertinib in EGFR exon 20 insertion-mutant NSCLC did not meet its primary PFS endpoint.
EGFR PACC Mutations | 07/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members